Alnylam Pharmaceuticals

NEWS

The Day In Review: Biotech Takes A Beating

October 19, 2005

·

1 min read

Genetic Technique Used To Cut Cholesterol

October 19, 2005

·

1 min read

The Day In Review: Biotech Outpaces Market As A Whole

October 19, 2005

·

1 min read

The Day In Review: January Off To A Bad Start

October 19, 2005

·

1 min read

AWARDS

JOBS

IN THE PRESS

Business

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity

February 6, 2020

·

30 min read

Policy

Alnylam Receives Positive CHMP Opinion for GIVLAARI™ (givosiran) for the Treatment of Acute Hepatic Porphyria in Adults and Adolescents

January 31, 2020

·

10 min read

Business

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Financial Results

January 27, 2020

·

2 min read

Business

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2019 Global Net Product Revenues and Provides Additional Commercial Updates

January 12, 2020

·

14 min read

Genetown

Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1)

January 10, 2020

·

8 min read

Genetown

Alnylam to Webcast Presentation at 38th Annual J.P. Morgan Healthcare Conference

January 6, 2020

·

2 min read

Drug Development

Alnylam Reports Positive Topline Results from ILLUMINATE-A Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1

December 17, 2019

·

12 min read

Genetown

Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day

November 22, 2019

·

13 min read

FDA

Alnylam Announces New and Enhanced Framework for Value-Based Agreements to Accelerate Patient and Provider Access to GIVLAARI™ (givosiran)

November 20, 2019

·

15 min read

FDA

Alnylam Announces Approval of GIVLAARI™ (givosiran) by the U.S. Food and Drug Administration (FDA)

November 20, 2019

·

16 min read